天坛生物高管辞职,长春高新拟赴港上市,恒瑞医药1类新药获批临床,罗欣药业拟定增募资8.42亿元

谈医说药
Sep 29

百诚医药:近日获悉,公司自主研发的创新药BIOS-0623-Z4片获得国家药品监督管理局(NMPA)临床试验批准通知书。BIOS-0623-Z4片是由公司自主研发的一种非阿片类靶点机制应用于成人癌痛治疗的药物,目前无同靶点且同适应症药品上市。药品名称:BIOS-0623-Z4片,注册分类:1类,适应症:缓解成人癌痛,申请人:杭州百诚医药科技股份有限公司,受理号:CXHL2500675、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10